![CD127 is expressed in the majority of BCP-ALL and T-ALL cases. CD127 surface expression was prospectively measured via flow cytometry in 371 diagnostic blood or BM samples of patients with BCP-ALL and T-ALL in accordance with International-BFM-FLOW recommendations.19,20 CD127 low positivity was defined as ≥10% CD127+ ALL cells by flow cytometry and high expression as ≥50% CD127+ blasts within the CD45dim/CD19+ (BCP-ALL) or CD45dim/CD7+ (T-ALL) cell population, respectively. (A-C) Pie charts depicting the ratio of patients with CD127-negative, CD127-low, and CD127-high ALL among all analyzed patient samples (A), BCP-ALL (B), and T-ALL cases only within the cohort (C). (D) Comparison of percentage of CD127+ ALL cells in BCP-ALL vs T-ALL cases; ∗∗P = .0023, unpaired 2-sided t test. (E) Ratio of CD127+ ALL cells in different BCP-ALL subgroups. The stratification relevant lesions ETV6::RUNX1, BCR::ABL1, TCF3::PBX1, and KMT2A-rearrangements (KMT2A-r) were diagnosed by fluorescence in situ hybridization or RNA sequencing. Further genetic alterations (CRLF2-rearrangements [CRLF2-r], TP53-mutations [TP53-mut], and ZNF384-fusions [ZNF384]) were detected within the “B-others” subgroup (BCP-ALL cases without ETV6::RUNX1, BCR::ABL1, TCF3::PBX1, and KMT2A-r). Blue lines show the cutoffs for low and high CD127-positivity. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/143/26/10.1182_blood.2023021088/3/blood_bld-2023-021088-gr1.jpeg?Expires=1724247371&Signature=VHq28UOXSSGljVclQ3oBuhhNU2LFUYMW0BAsklKrtbY9XJ2873bBiqCsWVNKfi~D3hFyzZWh4XmJ9eTU16NpOoBHs9Z35MlGEmlvhwtkYy6m9wUn5A0afKYZdHtBFLfg1W2TAapQcUlmFyFxZI6JUM-WuZbknc8-bSbjX1ihMvGseMgSmgpsjmlasBfBAIoybp58B80QqONORpy1i3DNwiPjikrBVk6dnf3E2IfLnyzLwS6L7HA~LWDCv9dH2fXBTaDu30yhCO9RoK8jl5UnflFxrSQL~zVQrhICBdtIhKrHRI95Zkt~Y1zmEIKGG5T20Ph5eaq3DZoyPOUQ30uopA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CD127 is expressed in the majority of BCP-ALL and T-ALL cases. CD127 surface expression was prospectively measured via flow cytometry in 371 diagnostic blood or BM samples of patients with BCP-ALL and T-ALL in accordance with International-BFM-FLOW recommendations.19,20 CD127 low positivity was defined as ≥10% CD127+ ALL cells by flow cytometry and high expression as ≥50% CD127+ blasts within the CD45dim/CD19+ (BCP-ALL) or CD45dim/CD7+ (T-ALL) cell population, respectively. (A-C) Pie charts depicting the ratio of patients with CD127-negative, CD127-low, and CD127-high ALL among all analyzed patient samples (A), BCP-ALL (B), and T-ALL cases only within the cohort (C). (D) Comparison of percentage of CD127+ ALL cells in BCP-ALL vs T-ALL cases; ∗∗P = .0023, unpaired 2-sided t test. (E) Ratio of CD127+ ALL cells in different BCP-ALL subgroups. The stratification relevant lesions ETV6::RUNX1, BCR::ABL1, TCF3::PBX1, and KMT2A-rearrangements (KMT2A-r) were diagnosed by fluorescence in situ hybridization or RNA sequencing. Further genetic alterations (CRLF2-rearrangements [CRLF2-r], TP53-mutations [TP53-mut], and ZNF384-fusions [ZNF384]) were detected within the “B-others” subgroup (BCP-ALL cases without ETV6::RUNX1, BCR::ABL1, TCF3::PBX1, and KMT2A-r). Blue lines show the cutoffs for low and high CD127-positivity. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.
